Gilead Sciences, Inc.

Orsobio, Inc.

The Liver Company Inc.

Julie Farand

Zhimin Du

John O Link

William John Watkins

Darryl Kato

Gregory Notte

Kevin S Currie

Chandrasekar Venkataramani

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Michael Sangi

Kin Shing Yang

Doris T Tang

James B C Mack

Tezcan Guney

Peiyuan Wang

Barton W Phillips

Christian Gege

Jiayao Li

Joshua A Kaplan

Anna Zagorska

Brian P Bestvater

Jeff A Zablocki

Scott A Mitchell

Hyung-Jung Pyun

Scott E Lazerwith

Zheng-Yu Yang

Jennifer R Zhang

Sheila M Zipfel

Seung H Lee

Juan A Guerrero

Zhongdong Zhao

Aaron C Schmitt

Adam James Schrier

Ashley Anne Katana

Kirk L Stevens

Jayaraman Chandrasekhar

David Sperandio

Jennifer R Lo

Nicholas Mai

Casey Lockwood Olen

Dong Min Mun

Michael Graupe

Scott D Schroeder

Gediminas J Brizgys

Chienhung Chou

Qiaoyin Wu

Roland D Saito

Hang Chu

Jin-Ming Xiong

JinMing Xiong

James BC Mack

Jinming Xiong

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).

LPA receptor antagonists and uses thereof

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

FXR (NR1H4) modulating compounds

Therapeutics compounds for HIV virus infection

Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).

Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof

The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, X, X, R, R, R, R, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Syk inhibitors

Growing community of inventors

San Mateo, CA, United States of America

Julie Farand